# Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

> **NCT03256136** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 9 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Nivolumab
- **DRUG:** pemetrexed
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03256136
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-22
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03256136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03256136, "Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03256136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*